New combo therapy aims to keep lymphoma at bay after transplant
NCT ID NCT04491370
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether a drug called polatuzumab vedotin can safely help control lymphoma after a stem cell transplant. About 20 people with B-cell or Hodgkin lymphoma who have had a relapse or not responded to prior treatment will receive the drug if their disease is stable after transplant. The goal is to see if this approach can prevent the cancer from coming back.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- polatuzumab vedotin
- What this could lead to
- If this works, it could offer a way to keep lymphoma from coming back after a stem cell transplant, potentially improving long-term control of the disease.
- What could go wrong
- This is an early-phase trial with only 20 participants, so results may not apply to everyone. The drug can cause serious side effects, and it's unclear if it will improve outcomes compared to standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
New York Medical Center
RECRUITINGValhalla, New York, 10595, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Engineered immune cells take aim at Hard-to-Treat lymphomas